49773-26-4

Usage

Uses

Used in Pharmaceutical Research and Development:
4-ETHOXY-N-HYDROXY-BENZAMIDINE is utilized as a potential drug candidate for various therapeutic applications due to its potential anticoagulant, antithrombotic, or anti-inflammatory properties. Its ability to inhibit specific enzymes or proteins in the body makes it a promising compound for the development of new medications.
Used in Enzyme or Protein Inhibition:
In the field of medicinal chemistry, 4-ETHOXY-N-HYDROXY-BENZAMIDINE is used as an enzyme or protein inhibitor, leveraging its capacity to interfere with biological processes that may contribute to disease states such as coagulation disorders or inflammatory conditions.
Used in Bioavailability and Metabolism Studies:
The ethoxy group in 4-ETHOXY-N-HYDROXY-BENZAMIDINE is recognized for its contribution to the compound's pharmacological activity, making it a subject of interest in studies focused on improving drug bioavailability and understanding its metabolism within the body.
Further research is necessary to delineate the specific applications and optimize the use of 4-ETHOXY-N-HYDROXY-BENZAMIDINE in medical and pharmaceutical contexts.

Upstream product

• 25117-74-2 4-ethoxybenzonitrile 

Downstream Products

• 937626-96-5 5-(chloromethyl)-3-(4-ethoxyphenyl)-1,2,4-oxadiazole 
• 1229114-82-2 {5-chloro-2-[(3-(4-ethoxyphenyl)-1,2,4-oxadiazol-5-yl)-methoxy]-phenyl}-(phenyl)-methanone 
• 95844-45-4 N-(3-chloro-propionyloxy)-4-ethoxy-benzamidine 

Relevant academic research and scientific papers

In vitro anti-TB properties, in silico target validation, molecular docking and dynamics studies of substituted 1,2,4-oxadiazole analogues against Mycobacterium tuberculosis

The alarming increase in multi- and extensively drug-resistant (MDR and XDR) strains of Mycobacterium tuberculosis (MTB) has triggered the scientific community to search for novel, effective, and safer therapeutics. To this end, a series of 3,5-disubstitu

Small Molecule Inhibition of MicroRNA miR-21 Rescues Chemosensitivity of Renal-Cell Carcinoma to Topotecan

Chemical probes of microRNA (miRNA) function are potential tools for understanding miRNA biology that also provide new approaches for discovering therapeutics for miRNA-associated diseases. MicroRNA-21 (miR-21) is an oncogenic miRNA that is overexpressed in most cancers and has been strongly associated with driving chemoresistance in cancers such as renal cell carcinoma (RCC). Using a cell-based luciferase reporter assay to screen small molecules, we identified a novel inhibitor of miR-21 function. Following structure-activity relationship studies, an optimized lead compound demonstrated cytotoxicity in several cancer cell lines. In a chemoresistant-RCC cell line, inhibition of miR-21 via small molecule treatment rescued the expression of tumor-suppressor proteins and sensitized cells to topotecan-induced apoptosis. This resulted in a >10-fold improvement in topotecan activity in cell viability and clonogenic assays. Overall, this work reports a novel small molecule inhibitor for perturbing miR-21 function and demonstrates an approach to enhancing the potency of chemotherapeutics specifically for cancers derived from oncomir addiction.

Design, microwave assisted synthesis and characterization of substituted 1,2,4-oxadiazole analogues as promising pharmacological agents

Microwave assisted synthesis of a series of 3,5-disubstituted-1,2,4-oxadiazole analogues (3a-j) has been achieved between 5-(chloromethyl)-3-substituted phenyl-1,2,4-oxadiazoles (2a-j) and substituted benzophenone in presence of potassium carbonate in ace

Design, synthesis, characterization, and antibacterial activity of {5-chloro-2-[(3-substitutedphenyl-1,2,4-oxadiazol-5-yl)-methoxy]-phenyl} -(phenyl)-methanones

In the present investigation, a series of novel {5-chloro-2-[(3-(substitutedphenyl)-1,2,4-oxadiazol-5-yl)-methoxy]-pheny l}-(phenyl)-methanones (3a-i) have been synthesized from 5-(chloromethyl)-3-substitutedphenyl-1,2,4-oxadiazole (2a-i). The newly synth